| 拓扑替康联合顺铂治疗非小细胞肺癌的临床观察 |
| |
| 引用本文： | 邵江河,黄凤鸣,付建伟.拓扑替康联合顺铂治疗非小细胞肺癌的临床观察[J].贵州医药,2002,26(8):692-693. |
| |
| 作者姓名： | 邵江河 黄凤鸣 付建伟 |
| |
| 作者单位： | 1. 重庆市肿瘤研究所,401000
2. 重庆市医疗急救中心肿瘤科,401000 |
| |
| 摘 要： | 目的：观察拓扑替康联合顺铂治疗晚期非小细胞肺癌的临床疗效及毒性反应。方法：观察组使用拓扑替康联合顺铂治疗晚期非小细胞肺癌29例。对照组30例晚期非小细胞肺癌使用EP、CAP方案。结果：观察组总有效率55．17％，对照组总有效率33．33％，P＜0．05，差异有显著意义，但观察组血液系统毒性反应程度及发生率均高于对照组，P＞0．05，差异无显著意义，两组非血液性毒性反应相似，肝、肾功能基本正常。结论：观察组疗效确切，毒性反应可以耐受，说明拓扑替康联合顺铂治疗晚期非小细胞肺癌较好的疗效，具有进一步临床应用的价值。
|
| 关 键 词： | 治疗 拓扑替康 顺铂 非小细胞肺癌 疗效 毒性反应 |
Clinical observation of Topotecan combined Cisplatin in adranced non- snall cell lung cancer |
| |
| Shao Jianghe,Huang Fengming,Fu Jianwei.Chongqing Institute of Oncology,Chongqing.Clinical observation of Topotecan combined Cisplatin in adranced non- snall cell lung cancer[J].Guizhou Medical Journal,2002,26(8):692-693. |
| |
| Authors: | Shao Jianghe Huang Fengming Fu JianweiChongqing Institute of Oncology Chongqing |
| |
| Institution: | Shao Jianghe,Huang Fengming,Fu Jianwei.Chongqing Institute of Oncology,Chongqing,401000 |
| |
| Abstract: | Objective To evaluate the effects and safely of topotecan combined cisplatin in advanced non-small cell lung cancer (NSCLC). Methods 59 cases of advanced NSCLC were randomly divided into observed group and controled group. 29 cases of ovserved group were treated with topotecan and cisplatin. 30 cases of control group were treated with CTX+ADM+DDP (CAP) or VP-16+DDP (EP). Results The response rate of observed group and controled group were 55.17% (16/29) and 33.33% (10/30) respectively ( P <0.05).Hematologic toxicity observed group were higher than control group ( P >0.05). Conclusion Topotecan and Cisplatin can be combined safely. Response rate compare favoratly for NSCLC. |
| |
| Keywords: | Topotecan Cisplatin NSCLC |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
